Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study

The Lancet HIV

Volumn 3, Issue 7, 2016, Pages e289-e296

  Smith, Jennifer A ^a   Anderson, Sarah Jane ^a   Harris, Kate L ^b   McGillen, Jessica B ^a   Lee, Edward ^b,c   Garnett, Geoff P ^b   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

^c BOSTON CONSULTING GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ARTICLE; CIRCUMCISION; CONDOM USE; COUNSELING; HEALTH CARE COST; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL RING; MATHEMATICAL MODEL; MEDICAL DEVICE; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS TRANSMISSION; ADOLESCENT; ADULT; CONDOM; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; PROCEDURES; THEORETICAL MODEL; TRENDS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CIRCUMCISION, MALE; CONDOMS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PRE-EXPOSURE PROPHYLAXIS; SOUTH AFRICA; YOUNG ADULT;

EID: 84991388015     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30036-4     Document Type: Article

References (37)

1. 1 UNAIDS. On the fast-track to end AIDS by 2030: focus on location and population, 2015, UNAIDS, Geneva.
2. 2 Tanser, F, Bärnighausen, T, Grapsa, E, Zaidi, J, Newell, M-L, High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339 (2013), 966–971.
3. 3 Halperin, DT, Mugurungi, O, Hallett, TB, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe?. PLoS Med, 8, 2011, e1000414.
4. 4 Nelson, KE, Celentano, DD, Eiumtrakol, S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 335 (1996), 297–303.
5. 5 UNAIDS. Fast-track: ending the AIDS epidemic by 2030, 2014, UNAIDS, Geneva.
6. 6 Anderson, S-J, Cherutich, P, Kilonzo, N, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet 384 (2014), 249–256.
7. 7 Kerr, CC, Stuart, RM, Gray, RT, et al. Optima: a model for HIV epidemic analysis, program prioritization, and resource optimization. J Acquir Immune Defic Syndr 69 (2015), 365–376.
8. 8 Schwartländer, B, Stover, J, Hallett, T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377 (2011), 2031–2041.
9. 9 Hargreaves, JR, Delany-Moretlwe, S, Hallett, TB, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. Lancet HIV 3 (2016), e318–e322.
10. 10 Baeten, JM, Palanee-Phillips, T, Brown, ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med, 2016, 10.1056/NEJMoa1506110 published online Feb 22.
11. 11 Nel, A, Kapiga, S, Bekker, L-G, Devlin, B, Borremans, M, Rosenberg, Z, Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African women. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; 2016. http://www.croiconference.org/sessions/safety-and-efficacy-dapivirine-vaginal-ring-hiv-1-prevention-african-women (accessed May 25, 2016).
12. 12 Markowitz, M, Frank, I, Grant, R, et al. ÉCLAIR: phase 2A safety and PK study of cabotegravir LA in HIV-uninfected men. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; 2016. http://www.croiconference.org/sessions/eclair-phase-2a-safety-and-pk-study-cabotegravir-la-hiv-uninfected-men (accessed May 25, 2016).
13. 13 ClinicalTrials.gov. Study to evaluate the safety, tolerability and acceptability of long acting injections of the human immunodeficiency virus (HIV) integrase inhibitor, GSK1265744, in HIV uninfected men (ECLAIR). 2016. https://clinicaltrials.gov/ct2/show/NCT02076178 (accessed April 20, 2016).
14. 14 ClinicalTrials.gov. Evaluating the safety, tolerability, and pharmacokinetics of an investigational, injectable HIV medicine (GSK1265744) in HIV-uninfected adults. 2015. https://clinicaltrials.gov/ct2/show/NCT02178800 (accessed April 20, 2016).
15. 15 Caskey, M, Klein, F, Lorenzi, JCC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
16. 16 Global HIV Vaccine Enterprise. P5 partnership. http://www.vaccineenterprise.org/content/P5Partnership, 2015 (accessed Jan 4, 2015).
17. 17 Pinkerton, SD, Abramson, PR, Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44 (1997), 1303–1312.
18. 18 Auvert, B, Taljaard, D, Lagarde, E, Sobngwi-Tambekou, J, Sitta, R, Puren, A, Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med, 2, 2005, e298.
19. 19 Bailey, RC, Moses, S, Parker, CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369 (2007), 643–656.
20. 20 Gray, RH, Kigozi, G, Serwadda, D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369 (2007), 657–666.
21. 21 Cohen, MS, Chen, YQ, McCauley, M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
22. 22 Donnell, D, Baeten, JM, Bumpus, NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 66 (2014), 340–348.
23. 23 Cremin, I, Alsallaq, R, Dybul, M, Piot, P, Garnett, G, Hallett, TB, The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 27 (2013), 447–458.
24. 24 Shisana, O, Rehle, T, Simbayi, LC, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town. http://www.hsrc.ac.za/uploads/pageContent/4565/SABSSM%20IV%20LEO%20final.pdf, 2014 (accessed May 25, 2016).
25. 25 Dorrington, R, Johnson, L, Budlender, D, ASSA2008 AIDS and demographic models user guise (beta version), 2010, Centre for Actuarial Research, University of Cape Town, Cape Town.
26. 26 Weller, SC, Davis-Beaty, K, Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev, 1, 2002 CD003255.
27. 27 Baeten, JM, Donnell, D, Ndase, P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367 (2012), 399–410.
28. 28 Thigpen, MC, Kebaabetswe, PM, Paxton, LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367 (2012), 423–434.
29. 29 Bashorun, A, Nguku, P, Kawu, I, et al. A description of HIV prevalence trends in Nigeria from 2001 to 2010: what is the progress, where is the problem?. Pan Afr Med J, 18(suppl 1), 2014, 3.
30. 30 Maurice, J, South Africa's battle against HIV/AIDS gains momentum. Lancet 383 (2014), 1535–1536.
31. 31 Department of Health SA, South African National AIDS Council. South African HIV and TB investment case—reference report phase 1. http://sanac.org.za/wp-content/uploads/2016/03/1603-Investment-Case-Report-LowRes-18-Mar.pdf, 2016 (accessed May 25, 2016).
32. 32 McGillen J, Anderson S-J, Dybul M, Hallett TB. Optimising resource allocation to reduce HIV incidence across sub-Saharan Africa. Lancet HIV (in press).
33. 33 Panovska-Griffiths, J, Vassall, A, Prudden, HJ, et al. Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One, 9, 2014, e107066.
34. 34 Alistar, SS, Long, EF, Brandeau, ML, Beck, EJ, HIV epidemic control—a model for optimal allocation of prevention and treatment resources. Health Care Manag Sci 17 (2013), 162–181.
35. 35 Juusola, JL, Brandeau, ML, HIV treatment and prevention: a simple model to determine optimal investment. Med Decis Making 36 (2016), 391–409.
36. 36 Nichols, BE, Baltussen, R, van Dijk, JH, et al. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr 66 (2014), 221–228.
37. 37 Gerberry, DJ, Wagner, BG, Garcia-Lerma, JG, Heneine, W, Blower, S, Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in sub-Saharan Africa. Nat Commun, 5, 2014, 5454.